Principal IT Analyst - Veeva RIM

Biogen Inc. $BIIB stock: Wedbush Securities Inc. grows stake. Wedbush Securities Inc. increased its holdings in Biogen Inc. (NASDAQ:BIIB - Free Report) by 1,391.8% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 17,364 shares of the biotechnology company's stock after purchasing an additional 16,200 shares during the period. Wedbush Securities Inc.'s holdings in Biogen were worth $3,922,000 as of its most recent SEC filing. Several other institutional investors and hedge funds also recently made changes to their positions in the business. BlackRock Inc. purchased a new position in Biogen in the 2nd quarter worth $3,453,878,000. Primecap Management Co. CA purchased a new stake in Biogen during the second quarter valued at about $3,274,304,000. Legal & General Group Plc purchased a new stake in Biogen during the second quarter valued at about $322,640,000. Bank of America Corp DE purchased a new stake in Biogen during the second quarter valued at about $241,172,000. Finally, Deutsche Bank AG bought a new position in shares of Biogen during the second quarter valued at about $193,165,000. Institutional investors own 87.93% of the company's stock. Biogen trading down 1.2%. NASDAQ:BIIB traded down $3.15 during mid-day trading on Friday, reaching $250.69. 1,157,351 shares of the company's stock traded hands, compared to its average volume of 1,296,961. Biogen Inc. has a 12-month low of $138.00 and a 12-month high of $254.41. The firm has a market capitalization of $37.04 billion, a price-to-earnings ratio of 44.37, a PEG ratio of 2.83 and a beta of 0.09. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26. The company has a 50 day moving average price of $223.60 and a 200-day moving average price of $206.04. Biogen (NASDAQ:BIIB - Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, beating analysts' consensus estimates of $2.94 by $0.66. Biogen had a return on equity of 11.18% and a net margin of 8.32%. The business had revenue of $2.74 billion during the quarter, compared to analyst estimates of $2.46 billion. During the same quarter in the prior year, the company posted $5.47 EPS. Biogen's quarterly revenue was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, sell-side analysts predict that Biogen Inc. will post 12.29 earnings per share for the current year. Wall street analysts forecast growth. BIIB has been the topic of several analyst reports. Mizuho lifted their price objective on Biogen from $221.00 to $241.00 and gave the stock an "outperform" rating in a report on Tuesday, August 4th. Guggenheim raised their price target on Biogen from $260.00 to $280.00 and gave the stock a "buy" rating in a research report on Tuesday, July 21st. Canaccord Genuity Group lifted their price target on Biogen from $245.00 to $248.00 and gave the stock a "buy" rating in a research note on Thursday, July 30th. HC Wainwright boosted their price objective on Biogen from $237.00 to $251.00 and gave the company a "buy" rating in a research report on Thursday, July 30th. Finally, Wedbush increased their price objective on Biogen from $201.00 to $215.00 and gave the company a "neutral" rating in a research note on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $241.89. Biogen profile. Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer's disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions. The company's portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer's disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars. Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts. Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.

Biogen shares rose 5% after BofA raised its price target to $244 from $219 and kept a Neutral rating. The bank expects a "relatively quiet" third quarter. TD Cowen also lifted its target to $250 from $225 a day earlier. The stock now trades above both targets. The consensus target has climbed 43% in a year to $247, and the forward price-to-earnings ratio is near its five-year high of about 20. Second-quarter revenue rose 3% to $2.7 billion. Analysts expect about 6% growth this year and 2% to 3% a year through 2028. Biogen reports third-quarter results on October 28. It has warned that charges of $290 million to $320 million will cut earnings per share by $1.75 to $1.95.

The 52-week-high list: 23 Mid Cap names on Tuesday. October 21st, 2026 · by Trefis Team SPYYTD+14.0% SPYYTD+14.0% QQQYTD+18.3% As of Tuesday, October 20, there are 23 Mid Cap US and Canada-listed stocks in the Trefis coverage universe trading at their 52-week highs. Mid Cap here means a market value between $10 billion and $40 billion, the upper figure excluded. At about $35.9 billion in market value, Biogen (BIIB) is the largest company on the list; its stock is up 11.0% over the past month and up 70.0% over the past year. Health Care contributed the most names, 7 of the 23. For context, the S&P 500 is down 0.6% over the past month, including dividends. The 10 Largest, By Market Cap The table below shows the 10 largest of the 23 names, sorted by market capitalization, with returns over four windows: | Tickers | Market Cap | 1D Return | 1W Return | 1M Return | 1Y Return | | BIIB | $35.9 Bil | 4.1% | 6.2% | 11.0% | 70.0% | | CNC | $35.0 Bil | 3.2% | 2.8% | 9.0% | 100.8% | | WSM | $29.9 Bil | 1.8% | 6.2% | 12.1% | 38.9% | | SN | $28.1 Bil | 5.2% | 5.3% | 18.6% | 111.6% | | WST | $27.5 Bil | 1.3% | 4.6% | 7.5% | 44.1% | | CHD | $25.1 Bil | 1.8% | 5.8% | 11.0% | 21.3% | | IFF | $23.3 Bil | 0.3% | 3.4% | 9.1% | 46.3% | | PR | $20.8 Bil | 0.2% | 2.4% | 13.1% | 109.1% | | OVV | $19.7 Bil | 0.4% | 5.4% | 16.8% | 99.9% | | APA | $17.6 Bil | 0.3% | 3.9% | 13.9% | 129.3% | The Businesses Behind The Largest New Highs Biogen (BIIB) grew revenue 0.3% over the last twelve months and earned an operating margin of 19.3%. Centene (CNC) grew revenue 13.9% over the last twelve months and earned an operating margin of 0.8%. Across the list, one-month moves range from +6.4% for American Financial (AFG) to +24.9% for Hasbro (HAS). The median stock on the list is up 46.7% over the past year. 9 of the 23 names are also S&P 500 members. A new high tells you what the market already believes. The harder question is which of these runs management itself is underwriting. Our Guidance Momentum screen tracks exactly that: stocks where the company raised its own forward numbers. Strength Is A Clue. It Is Not A Plan A stock at its 52-week high has momentum on its side, and momentum is a real force. It is also the most crowded signal in the market, and what separates a run that lasts from one that tops is usually the business underneath. Checking that business, across thousands of names, is how the Trefis High Quality (HQ) Portfolio is assembled: roughly 30 companies that pass the quality screens, rebalanced on rules. It has a track record of outpacing a benchmark that combines the S&P 500, the S&P MidCap 400, and the Russell 2000. Let the highs point; let the discipline decide.